ESMO 2018
ESMO 2018 Press Releases
- 2018 ESMO Immuno-Oncology Award Goes to Cornelis Melief
- Local Radiotherapy Improves Survival in Metastatic Prostate Cancer with Low Disease Burden
- Avelumab Plus Axitinib Significantly Improve Progression-Free Survival in Untreated Renal Cell Carcinoma
- ESMO 2018: Nivolumab in Combination with Iipilimumab Shows Promising Results in Patients with Advanced Form of Bladder Cancer
- Huge Variations Between Countries in Time for Reimbursement Decisions on New Cancer Drugs
ESMO 2018 Kidney Cancer
- ESMO 2018: Can Biology Help Guide Treatment Decisions in Renal Cancer?
- ESMO 2018: Challenging Established Frontline Therapies in Renal Cancer
- ESMO 2018: PRINCIPAL Study - Real-World Effectiveness of Pazopanib in Patients with Intermediate Prognostic Risk Advanced Renal Cell Carcinoma
- ESMO 2018: Activity of Cabozantinib After PD-1/PD-L1 Immune Checkpoint Blockade In Metastatic Clear Cell Renal Cell Carcinoma
- ESMO 2018: Safety and Tolerability of Atezolizumab plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma: IMmotion 150 and IMmotion 151
ESMO 2018 Prostate Cancer
- ESMO 2018: Preliminary results from TRITON2: A Phase II Study of Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer Associated with Homologous Recombination Repair Gene Alterations
- ESMO 2018: The Best of Munich 2018 Congress Genitourinary Tumors, Prostate
- ESMO 2018: Improving Treatment Outcome by Manipulating the Immune System
- ESMO 2018: Cabazitaxel Treatment in mCRPC Clinical Trials Compared to Usual Care In CAPRI: An Observational Study In The Netherlands
- ESMO 2018: Improving Outcome by Optimizing Combination and Sequencing of Treatments
ESMO 2018 Bladder Cancer
- ESMO 2018: ABACUS, A phase II Study Investigating the Safety and Efficacy of Neoadjuvant Atezolizumab in Muscle Invasive Bladder Cancer
- ESMO 2018: Comprehensive Biomarker Analyses and Updated Results of PURE-01 Study: Neoadjuvant Pembrolizumab in Muscle-Invasive Urothelial Bladder Carcinoma
- ESMO 2018: Is There Still a Role for Chemotherapy in Bladder Cancer?
- ESMO 2018: Overall Survival Results – RANGE, Ramucirumab and Docetaxel In Platinum-Refractory Urothelial Carcinoma
- ESMO 2018: Neoadjuvant Therapy with Pembrolizumab Alone or in Combination with Cisplatin plus Gemcitabine for Locally Advanced Urothelial Cancer, A Phase Ib/2 Study